Having trouble accessing articles? Reset your cache.

Novartis’ asthma failure weighs on Gossamer’s shares ahead of readout

The latest failure of asthma therapy fevipiprant from Novartis in two Phase III studies dimmed hopes for Gossamer’s lead program, which aims for the same target.

Novartis AG (NYSE:NVS; SIX:NOVN) said Monday that pooled results from the Phase III LUSTER-1 and LUSTER-2 trials do not support fevipiprant’s ongoing development in asthma.

Read the full 500 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers